Company / Cash & Equivalents
Niagen Bioscience, Inc. Cash & Equivalents History
FY2019-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$28.2M
FY2021
5-year range
$28.2M / $28.2M
FY2019-FY2021
Trend
+69.0%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $19M to $28M over the past 2 years.
Based on SEC 10-K filings.
$28M in FY2021.
Improved from $19M to $28M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, cash & equivalents increased 69.0% year-over-year.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $28.2M | +69.0% |
| FY2020 | $16.7M | -11.2% |
| FY2019 | $18.8M | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026